Home Newsfeeds Needham Maintains Buy on Uber Technologies, Raises Price Target to $52

Needham Maintains Buy on Uber Technologies, Raises Price Target to $52

Needham analyst Bernie McTernan maintains Uber Technologies (NYSE:UBER) with a Buy and raises the price target from $50 to $52.

byBenzinga Newsdesk

August 3, 2022

1 minute read

Needham analyst Bernie McTernan maintains Uber Technologies (NYSE:UBER) with a Buy and raises the price target from $50 to $52.

TravelCenters Of America Q4 EPS $2.99 Beats $1.34 Estimate, Sales $2.66B Beat $2.65B Estimate

By Bill Haddad

February 28, 6:14 PM

TravelCenters Of America (NASDAQ:TA) reported quarterly earnings of $2.99 per share which beat the analyst consensus estimate of $1.34 by 123.13 percent. This is a 235.96 percent increase over earnings of $0.89 per share

Elon Musk’s xAI Startup Aims To Secure $1B In Equity Funding

By Ananya Gairola

December 5, 11:40 PM

Elon Musk's AI venture, xAI, aims to secure $1 billion in equity funding to strengthen its position in the AI industry, with $135 million already raised, as the company seeks to understand the nature of the universe and competes with other AI companies.

MSFT

Avalo Announces It Has Completed Targeted Enrollment Of 80 Patients In Phase 2 PEAK Trial Of AVTX-002 In Non-Eosinophilic Asthma

By Benzinga Newsdesk

January 17, 8:10 AM

Avalo Therapeutics, Inc. (NASDAQ:AVTX), today announced that it completed enrollment of the 80 patients targeted for the Phase 2 PEAK Trial evaluating AVTX-002 (anti-LIGHT mAb) in patients with Non-Eosinophilic Asthma

AVTX

Fed Meeting Preview: Is A March Rate Cut Likely?

By Piero Cingari

January 29, 2:57 PM

Fed likely to keep rates unchanged at 5.25-5.5% in upcoming FOMC meeting, but focus on whether aggressive rate cuts are warranted.

SPY

Needham Maintains Buy on Uber Technologies, Raises Price Target to $52

Related Posts

TravelCenters Of America Q4 EPS $2.99 Beats $1.34 Estimate, Sales $2.66B Beat $2.65B Estimate

Elon Musk’s xAI Startup Aims To Secure $1B In Equity Funding

Avalo Announces It Has Completed Targeted Enrollment Of 80 Patients In Phase 2 PEAK Trial Of AVTX-002 In Non-Eosinophilic Asthma

Fed Meeting Preview: Is A March Rate Cut Likely?